SCHEMBL263764

SCHEMBL263764

Cn1nccc1C(=O)Nc1ccc(-c2ccc(Cl)cc2Cl)c(N)n1

nearest known ligand 0.86

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 12/20 0.86
SCN9A Q15858 2/20 0.70
SCN1A P35498 1/20 0.70
SCN5A Q14524 1/20 0.70
NPC1 O15118 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C19 P33261 1/20 0.56
RAB9A P51151 1/20 0.56
SCN2A Q99250 1/20 0.50
SCN3A Q9NY46 1/20 0.50
HTT P42858 2/20 0.46
MAP4K1 Q92918 1/20 0.44
DPP4 P27487 1/20 0.42
DPP8 Q6V1X1 1/20 0.42
DPP9 Q86TI2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL261800 0.93 SCN10A (1.00) SCN10ASCN9ASCN1ASCN5ANPC1
SCHEMBL14237364 0.89 SCN10A (1.00) SCN10ASCN9ASCN1ASCN5ANPC1
SCHEMBL261982 0.89 SCN10A (1.00) SCN10ASCN9ASCN1ASCN5ANPC1
SCHEMBL263595 0.88 SCN10A (1.00) SCN10ASCN9ASCN1ASCN5ANPC1
SCHEMBL14237512 0.85 SCN10A (0.83) SCN10ASCN9ASCN1ASCN5ANPC1
SCHEMBL14237636 0.85 SCN10A (0.63) SCN10ASCN9ASCN1ASCN5ANPC1
SCHEMBL263433 0.84 SCN10A (0.86) SCN10ASCN9ASCN1ASCN5ANPC1
SCHEMBL14237398 0.84 SCN10A (0.83) SCN10ASCN9ASCN1ASCN5ANPC1
SCHEMBL14237460 0.84 SCN10A (0.84) SCN10ASCN9ASCN1ASCN5ANPC1
SCHEMBL263763 0.83 SCN10A (0.80) SCN10ASCN9ASCN1ASCN5ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP claimed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US claimed
JP-4657384-B2 2011-03-23 JP claimed
JP-2010526050-A 2010-07-29 JP claimed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP claimed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US claimed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO claimed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 SCN10A 358/4885SCN9A 491/4885SCN1A 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.